P53基因治疗原发性肝癌的临床研究  

Clinical study of P53 gene therapy on primary hepatocarcinoma

作　　者：史守良[1] 董秀敏[1] 胡万宁[1] 马龙滨[1] 陈宝明[1] 韩敏利[1] 

机构地区：[1]河北省唐山市人民医院,河北唐山063000

出　　处：《现代中西医结合杂志》2012年第10期1036-1037,共2页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的观察P53基因治疗原发性肝癌的临床效果。方法将60例原发性肝癌患者随机分为试验组和对照组。试验组采用速溶表柔比星+今又生治疗,对照组采用速溶表柔比星+顺铂+氟尿嘧啶治疗。治疗1个月后观察2组患者血清P53蛋白水平、治疗效果和生存质量。结果 2组患者治疗后血清P53蛋白水平均有所升高,试验组治疗前后比较有显著性差异(P<0.05);试验组的治疗效果和生存质量明显优于对照组。结论 P53基因治疗能更好地抑制肿瘤的生长,改善患者的生存质量。Objective It is to observe the clinical effect of P53 gene therapy on primary hepatocareinoma. Methods 60 ca- ses of patients with primary hepatoearcinoma were randomly divided into two groups： test group treated with epirubicin and gendicine, and the control group treated with epirubicin, cisplatin and fluorouracil. After one month＇s treatment, plasma P53 protein level, treatment effect and survival quality were observed. Results The plasma P53 protein level was increased after treatment in both groups, and the level of the test group was significantly higher than that of the control group（ P 〈 0.05 ）. The treatment effect and survival quality of the test group was also better than that of the control group. Conclusion P53 gene therapy can effectively inhibit tumor growth and thus improve survival quality of the patients with primary hepatocarcinoma.

关 键 词：肝癌 P53基因 重组人P53腺病毒注射液 

分 类 号：R735.7[医药卫生—肿瘤]